



SEKISUI CHEMICAL CO., LTD.

Presentation of Strategic Area Map & Life Science Business

Keita Kato

President

June 29, 2022

Agenda

- | | |
|---|-----|
| 1. Sekisui Chemical Group Accomplishments | P2 |
| 2. FY2030 Long-term Vision | P3 |
| 3. Strategic Area Map | P7 |
| Overview of Medical Business | P13 |
| Long-term Vision of Life Science Business | P23 |

1. Sekisui Chemical Group Accomplishments

■ Guided by the “3S Principles,” SEKISUI CHEMICAL has dared to challenge new businesses and frontiers focusing mainly on plastics-related technologies and products since its foundation in 1947














The “3S Principles”

Service: At SEKISUI, we serve our stakeholders by creating social, environmental and economic value through responsible business practices.

Speed: At SEKISUI, we accelerate innovation by eagerly taking on new challenges, adapting to change and staying ahead of the times.


Superiority: At SEKISUI, we contribute to society by helping to solve social issues with our superior technologies and quality.



<p>1 1947</p> <p>Established SEKISUI INC. in order to run a general plastic business</p> 	<p>4 1962</p> <p>Rolled out poly-pail plastic garbage bins on a nationwide basis and contributed to efforts aimed at resolving garbage-related issues</p> 	<p>7 1979</p> <p>Awarded the Deming Prize, the highest honor for total quality management from production to sales and service</p> 	<p>10 2016</p> <p>Executive Advisor Naotake Okubo awarded the Deming Prize for Individuals; SEKISUI CHEMICAL Group awarded the Japan Quality Recognition Award in the Innovation category by the Union of Japanese Scientists and Engineers</p> 
<p>2 1952</p> <p>Began full-fledged production of ESLON polyvinyl chloride pipes</p> 	<p>5 1963</p> <p>Established SEKISUI PLASTICS CORPORATION, the first plant to be set up in the U.S. by a Japanese manufacturer</p> 	<p>8 2001</p> <p>Divisional company system introduced</p> 	<p>11 2017</p> <p>Successfully developed a first-in-the-world production technology that converts garbage into ethanol</p> 
<p>3 1958</p> <p>Began production of interlayer film for laminated lass S-LEC</p> 	<p>6 1971</p> <p>Entered the housing business with the launch of steel frame unit housing “Heim”</p> 	<p>9 2006</p> <p>Daiichi Pure Chemicals Co., Ltd. (currently Sekisui Medical Co., Ltd., a consolidated subsidiary) acquired</p> 	<p>12 2019</p> <p>Acquired AIM Aerospace Corporation (currently SEKISUI AEROSPACE CORPORATION)</p> 




2. Vision 2030 Overview of the Long-term Vision (1)

- To set the ideal future image for the Group and drive the transformation of the Group to achieve it, in 2020 the Sekisui Chemical Group established the Long-term Vision, **Vision 2030**.
- The Group aims to double its business by 2030 (to sales of ¥2 trillion and operating profit margin of 10% or higher), by expanding contributions to resolving social issues through innovation and creativity centered on ESG management.



2. Vision 2030 Overview of the Long-term Vision (2)


- Increase sales of each domain from 1.5 to 3 times, and transform into an attractive company with diverse growth engines and a strong presence
- Drive expansion by opening up frontiers without sacrificing speed of growth overseas
- To achieve dramatic growth beyond existing trend lines, the Group expects to invest over ¥2 trillion over the 10 years to 2030.



* HPP: High Performance Plastics Company, Housing: Housing Company, UIEP: Urban Infrastructure & Environmental Products Company

2. Vision 2030 Overview of the Long-term Vision (3)

Take up the challenge of pursuing innovation as an extension of core technologies and create new businesses in each domain



2. Toward Achieving the Long-term Vision, **Vision 2030**

Progress toward achieving the Long-term Vision, **Vision 2030**

- ✓ Specification of key areas in each domain
- ✓ Compartmentalization of each divisional company and group-wide fusion
- ✓ Targeted allocation of capital to realize business in key areas

The Group launched cross-divisional-company projects to

Formulate a Strategic Area Map

as a compass for realizing the Long-term Vision, **Vision 2030**

The Strategic Area Map concept

Residential

- (1) Housing construction business
(Housing, Renovation)
- (2) Real estate business
(Town and community development, Real estate)
- (3) Frontier
(Residential services, Overseas)

Advanced Lifeline

- (1) Social infrastructure
(Establish long-term, stable business)
- (2) Building and Living Environment
(Establish new business)
- (3) Advanced Materials
(Expand into growth markets)
- (4) New areas
(Expand contributions to solving social issues)

Innovative Mobility

- (1) Mobility
(From a component business to a module business)
- (2) Electronics
(Expansion to mobility and residential infrastructure components)
- (3) Building and Infrastructure
(Labor saving, Data utilization)

Life Science

- (1) Diagnostics business
- (2) Pharmaceutical sciences business
- (3) New areas
(Cell culture, Pharmaceutical new modalities, Pharmaceutical CDMO)

3. Strategic Area Map Social Issues Each Domain Aims to Solve

Innovation for the Earth

In order to realize sustainable society,
we support the basis of LIFE and will continue to create “peace of mind for the future”

Sales Target ¥2 trillion (Operating profit margin: 10% or higher)

Residential

Supporting people's peace of mind, safety and comfort

Advanced Lifeline

Solving infrastructure issues and supporting social infrastructure globally

Innovative Mobility

Providing materials for equipment which contribute to a sustainable lifestyle and society

Life Science

Supporting global health and longevity

Realization of a healthy and well-served society

(Healthy lives are ensured and social services are improved.)

Provision of disaster-resistant infrastructure, cities, residential environments and communication environments

(Sustainable infrastructure, Town and Community Development, residential environments and communication environments are provided.)

Use of water and energy resources

(Access to safe water and sustainable energy are ensured.)


Production that uses labor, resources and the environment sustainably

(Zero carbon and a recycling society are achieved.)

Next Frontier


3. Strategic Area Map

- We will move forward with key allocation of capital to expand areas for strengthening, aiming to fusion and composite areas of innovation.
- Management resources will be allocated in a targeted manner to build the Life Science business into a fourth divisional company.



3. Strategic Area Map (1) Lightweight, high-strength materials (CFRP)




- Sekisui Aerospace is strengthening synergies with Sekisui Chemical Group in lightweight, high-strength materials, including businesses involving the aircraft and medical fields. In addition to opening new markets and developing products using advanced technologies, the Group is pursuing an area expansion strategy.




3. Strategic Area Map (2) Next-generation communication components

The Group will strengthen its product line related to electromagnetic-wave management, based on transparent & flexible radio-wave reflection film. We will expand operations, embracing radio-wave-environment design services.


Transparent & flexible radio-wave reflection film

Appearance & function		
	<p>Radio waves</p> <p>Visible light</p>	
Structure		
	<p>Special coating layer</p> <p>Highly Transparent PSA</p> <p>Meta-material layer*</p> <p>Special PSA</p> <p><small>*Technical support by Meta Materials Inc.</small></p>	
Characteristics	Issues (5G/6G)	•Switch to high frequency results in high directionality of communication radio waves, fostering attenuation. Improvement of the communication environment is required.
	Performance	•Highly transparent and durable, yet achieves scattering reflection performance equal to or better than aluminum plates.
	Outside partnerships	•The special meta-material layer was designed through a technical partnership with Meta Materials Inc.



3. Strategic Area Map (2) Next-generation communication components


■ Overview of product line for electromagnetic-wave management
(For reference: Schematic view)



3. Strategic Area Map (3) Smart city strategy

Leveraging the strengths of the housing business, Group-internal and external knowledge will be concentrated to create resilient towns and communities that can solve social problems (towns and communities that are safe, secure and sustainable).

Schematic view of products and services that the Sekisui Chemical Group can provide in the “towns and communities” area





Overview of Medical Business

Eiichi Takahashi

President of SEKISUI MEDICAL CO., LTD.

Overview of Medical Business

The Medical Business consists of the **diagnostics business**, which sells diagnostic reagents and equipment; and the **pharmaceutical sciences business**, which consists of the pharmaceutical and fine chemicals business, which manufactures active pharmaceutical ingredients (APIs), etc. under contract; the drug development solutions business, which supports the R&D efforts of pharmaceutical companies; and the enzymes business, which manufactures precursors for diagnostic reagents and manufactures recombinant proteins under contract. Overseas sales account for the majority of total sales.

Business Areas

1 Diagnostics business

Development, manufacture and sale of diagnostic reagents and equipment as well as vacuum blood collection tubes, for the clinical chemistry, immunology, blood-coagulation and POC areas, among others



Blood Coagulation Analyzers S400CF



Blood Coagulation
Nanopia P-FDP

2 Pharmaceutical sciences business

Pharmaceutical and fine chemicals: CMO

Contract manufacture of APIs/intermediates/amino acids/peptides


Drug development solutions business: CRO

Contract research to support drug R&D


Enzymes business: CDMO

Manufacture and sales of precursors for diagnostic reagents and manufacture under contract of recombinant proteins

Sales by Business



Sales by Region



Timeline of the Medical Business

■ The Business is actively pursuing M&A and other strategic investments, fusing its processing technologies with changes made in anticipation of a new age. The Business boosted sales and operating profit more than 10-fold. (Compared to FY2005)

- FY2006: Using its microparticle control technology, the Group **entered the diagnostic area**, constructing a supply chain from materials to sales.
- FY2011: The Group acquired a business foundation for expanding operations overseas, **strengthening its overseas sales framework**.
- FY2015: The Group **expanded in the diagnostic area**, including cancer diagnostics, **acquiring new technologies**.
- FY2020: The Group conducted capital investment in the Medical Business, **strengthening productive capacity**.

2020

- Major investment decisions:
Iwate Plant: Strengthening of productive capacity
UK Plant: Establishment of CDMO framework

Phase 1 Expansion in the diagnostics business

2006

Acquired Daiichi Pure Chemicals

- Full-fledged entry into the diagnostics business

2011

Diagnostic reagent business acquired from Genzyme Corporation (U.S.)

- Acceleration of overseas development of the diagnostics business

2015 Phase2 Further expansion in the Medical Business


Acquired EIDIA

- Expansion in the diagnostic area, acquisition of new technologies

(Billions of yen)

Group core technologies

- Microparticle control technologies (latex)
- Microparticle compounding and design
- Fine formation processes
- Design of functional plastics




2005-2021

Cumulative investment in M&A, equipment strategy ¥100.0 billion Over

Cumulative EBITDA ¥172.7 billion

SEKISUI MEDICAL Global Operations





Number of overseas locations: 12 (include duplicates)

Diagnostics business:	11 locations
Enzymes business:	2 locations
Drug development solutions business:	1 location






Diagnostics Business: Overview

Development, manufacture and sale of diagnostic reagents and equipment for areas including clinical chemistry, immunology, diabetes and blood coagulation, as well as for vacuum blood collection tubes

Sales Composition




Diagnostic areas and sample products

Focus Areas	Clinical chemistry /Immunology	Blood coagulation	Diabetes
Main Products	 <p>Diagnostic reagents for cholesterol, neutral lipids, syphilis, Cancer, etc. Sample products: Cholestest N HDL PicoLumi PIVKA-II MONO</p>	 <p>Instruments and diagnostic reagents for coagulation and fibrinolysis Sample products: S400CF Nanopia P-FDP</p>	 <p>Diagnostic reagents for hemoglobin A1c, blood insulin, etc. Sample products: NORUDIA N HbA1c NORUDIA Insulin</p>
Focus Areas	POC* (Point of care)	Blood collection tubes	
Main Products	 <p>Instruments and diagnostic reagents for infectious diseases such as influenza, markers for heart disease, etc. Sample products: RapidTester FLU•NEXT Rapidopia II</p>	 <p>Plastic vacuum blood collection tubes for blood testing and components for serum separating agents, blood coagulation accelerants, etc. Sample products: Insepack II Minicollect II</p>	

*POC: Acronym for Point of Care; refers to timely onsite (clinics, etc.) diagnostics


Diagnostics Business: Overview of Clinical Reagent Market

- Growth in the clinical reagent market in Japan is trending at around 1–2% per year.
- Growth in the clinical reagent market overseas is trending at around 4% per year. Growth is slow in Europe and North America. China, India and Southeast Asia are driving the market, drawing closer to the European market in market size.
- The market is showing expansion in other regions (Central and South America, Oceania, Africa, etc.) as well.



Sources: Fuji Keizai, *Worldwide Clinical Reagent Market in 2019* (in Japanese)

Fuji Keizai, *Clinical Reagent Market in 2019 No. 4: General Analysis and Corporate Strategy* (in Japanese)



Source: Fuji Keizai, *Worldwide Clinical Reagent Market in 2019* (in Japanese)

Diagnostics Business : Business Strengths

- Supply chains are formed from materials and basic technology to development, commercialization and sales.
- Products from key factories in Japan, North America and China are sold worldwide through a global sales network.
- High market share is obtained in high-quality diagnostic reagents for clinical chemistry (HDL, LDL), diabetes and blood coagulation.

Diagnostics Business

	Clinical chemistry /Immunology	Blood coagulation	Diabetes	POC (Point of care)	Blood collection tubes
Development	Japan	Japan	Japan	Japan/North America/Singapore	Japan
Manufacture	Japan/Canada /China (Suzhou)	Japan /China (Suzhou)	Japan/Canada	Japan/North America/Singapore	Japan /China (Beijing)
Sales	Global network (10 sales offices in Japan, 3 in North America, 2 in Europe, 2 in China, 1 in ASEAN)				



SEKISUI MEDICAL Tsukuba Factory



SEKISUI DIAGNOSTICS , LLC, San Diego




SEKISUI MEDICAL TECHNOLOGY (SUZHOU) CO., LTD

Pharmaceutical Sciences Business: Overview

- The Pharmaceutical Sciences Business consists of the pharmaceutical and fine chemicals business, which produces APIs under contract (CMO); the drug development solutions business (CRO); and the enzymes business, which manufactures and sells precursors for diagnostic reagents and manufactures recombinant proteins under contract (CDMO).

Sales Composition



Pharmaceutical and fine chemicals

Manufacture of small-molecule APIs, intermediate substances, amino acids and peptides (Iwate)



Drug development solutions

Testing under contract for drug development (Ibaraki)



Enzymes

Manufacture and sales of precursors for diagnostic reagents, manufacture under contract of recombinant proteins (UK)




CMO: Contract manufacturing organization CDMO: Contract development and manufacturing organization CRO: Contract research organization

Pharmaceutical Sciences Business: Drug Development Process and Markets


■ This market is growing briskly as outsourcing of drug development increases.

Existing business

Drug development process



Pharmaceutical companies



Investment status

	Small molecule drugs	Peptide (medium-size molecule) pharmaceuticals	Therapeutic proteins
Development	—	○	○
Manufacture	○	○	○

Boost production capacity of active pharmaceutical ingredients and pharmaceutical intermediates (Iwate Plant)

Establish a CDMO structure of raw materials (U.K. Plant)

Source: Grand View Research
 "Pharmaceutical Contract Manufacturing & Research services market MARKET ESTIMATES & TREND ANALYSIS FROM 2018 TO 2030"

Pharmaceutical Sciences Business: CMO/CDMO Strengths

- Contracting of manufacture and development of diverse APIs from contractors in Japan and overseas
- Boosting market presence and share by reinforcing production systems in Japan and overseas
 - Increase in capacity for production of APIs and intermediates for small molecule drugs (Iwate Plant: Expected to start operations in March 2023)
 - Establishment of a CDMO system for materials for use in protein drugs (UK Plant: Expected to start operations in March 2024)

Support for various modalities

Small molecule drugs	Peptide (medium-size molecule) pharmaceuticals	Therapeutic proteins
Sekisui Medical	Sekisui Medical Partner: PeptiStar Inc.*	SEKISUI DIAGNOSTICS (UK)

*Joint-venture company primarily owned by SEKISUI CHEMICAL CO., LTD., PeptiDream Inc. and Shionogi & Co., Ltd.

Manufacturing and research facilities

CMO/CDMO facilities

2 locations in Japan
Sekisui Medical: Iwate Plant, Tsukuba Research Institute

1 location overseas
Sekisui Diagnostics (UK)



Sekisui Medical: Iwate Plant



SEKISUI DIAGNOSTICS (UK)



Life Science
Business
Long-term Vision


Futoshi Kamiwaki

Representative Director
Senior Managing Executive Officer
Head of Business Strategy Dept.

The Long-term Vision **Vision 2030** (Repeated)


- The Life Science business aims to reach sales of ¥200 billion to ¥250 billion in 2030 by expanding its business scope, strengthening existing areas and fusing with domains in the Sekisui Chemical Group.

(Net sales image: Billions of yen)



Life Science Business Toward Achieving the Long-term Vision

By integrating our core technologies with those we have obtained from R&D and M&A activities, we are extending our expertise in processing to the Pharmaceutical Sciences field and conducting “anticipatory innovation,” setting our sights on global healthcare development. In so doing, we are contributing significantly to solutions for society.



Net Sales

FY2021

Operating profit


EBITDA

Vision 2030

Life Science Business Long-term Vision

- Leveraging the Sekisui Chemical Group's strengths in technology and processing, we are expanding our contribution to solving issues in industries that support human health.

Shape of the Group's Life Science business in 2030



Toward Our Target State

- Accelerating growth in our current mainstay business, the Diagnostics Field
- Construction of new pillars of operations in the Pharmaceutical Sciences Field
- Creating new businesses through Group synergies with areas adjoining other domains

Diagnostics Field: Growth Orientation and Aims

Overseas FY2021: ¥42.6 billion → FY2030: ¥100 billion


■ Expansion of fields and areas through introduction of own-company products

US: Full-fledged entry into the genetic POC field through the MDx (molecular diagnostics) Development Center and development of own-company products

China: Tripling of business size by introducing new products in diagnostic reagents and devices and strengthening local production



Sales in the Long-term Vision for the Diagnostics Field
Sales target for 2030: ¥150 billion



In Japan FY2021: ¥29.1 billion → FY2030: ¥50 billion

■ Domain expansion by entering new areas and strengthening of existing businesses


New Areas, New Businesses

■ New areas: Immunological testing, genetic testing

■ New businesses: Self-care (home medical care, etc.), cancer screening


Pharmaceutical Sciences Field: Growth Orientation and Aims

■ By strengthening and expanding the API CDMO business base at an early stage and expanding into new drug modalities over the medium-to-long term, we aim to become a partner for advanced pharmaceutical companies and grow and improve profitability (expand the portfolio).



Sales in the Long-term Vision for the Pharmaceutical Sciences Field

Sales target for 2030: ¥100 billion




Pharmaceutical Sciences Field: 1st Step: API CDMO business

Target state as an API CDMO

A partner to pharmaceutical companies that can meet a variety of needs related to APIs and provide globally requested services in the development of innovative new drugs.

Role as an API CDMO

*Application by pharmaceutical companies for approval of pharmaceuticals




- Acceleration of strengthening of business foundations to achieve the target state as an API CDMO
- Aim to provide a wide range of services from development through manufacturing to pharmaceutical-affairs support, according to the degree of process

Pharmaceutical Sciences Field: 2nd Step: New drug modalities

- To respond to the growing diversification in drug modalities, we will contribute to the improvement of stability, productivity and other aspects of pharmaceutical manufacturing, using our processing capabilities based on core Group technologies. In this way we will achieve medium-to-long term growth by supporting health and longevity in societies worldwide.

Issues at each stage of development of pharmaceutical modalities



New modalities

Genetic therapies (Ex vivo)

- ✓ Achievement of effects through administration of cells impregnated with genes

Genetic therapies (In vivo)

- ✓ Achievement of effects through administration of vectors and viruses loaded with genes

Regenerative medicine

- ✓ Achievement of tissue regeneration through cell transplantation and tissue grafting

Mid-sized-molecule drugs

Peptide drugs

- ✓ Achievement of bioactive effects by administration of peptides consisting of chains of amino acids

Nucleic-acid drugs

- ✓ Achievement of effects by administration of nucleic acids such as DNA and RNA.

Antibody drugs

- ✓ Achievement of bioactive effects by administration of artificially created antibodies

Small-molecule drugs

- ✓ Pharmaceuticals consist of relatively small molecules
- ✓ Achievement of bioactive effects by administration of small-molecule compounds
- ✓ Drug development is growing more difficult with each passing year.

Pharmaceutical Sciences Field

2nd Step: Key fields in new drug modalities

- Strengthening partnerships to focus on peptide drugs, regenerative medicine and genetic therapies in new pharmaceutical modalities

Peptide drugs

PeptiStar Inc. was founded in September 2017 as a joint venture among SEKISUI CHEMICAL CO., LTD., PeptiDream Inc. and Shionogi & Co., Ltd. PeptiStar conducts research, development, manufacturing and sale of constrained peptide APIs.



Technology development through a Japan-wide framework

- ✓ Acceleration of development of synthesis, purification, freeze-drying and analytical technologies through a Japan-wide framework
- ✓ Joint research projects are currently under way with several companies.

Possession of the largest manufacturing equipment in Japan

- ✓ Possession of Japan's largest filter reactor (300L) and one of the nation's largest freeze-dryers (500L)
- ✓ Versatile production ranging from small samples to large-scale GMP production

Ability to submit proposals that suit customer needs

- ✓ Response to needs for speed, quality and low cost as a specialist in peptide API production
- ✓ Ability to handle peptides, which are exceptionally difficult to handle



Synergy with STag, the Group's own development technology

The STag peptide synthesizing method

STag is an original method of peptide synthesis developed by Sekisui Medical. This next-generation method of peptide synthesis is highly economical and eco-friendly, efficiently synthesizing even the most difficult-to-synthesize peptides.


Regenerative medicine

Cyfuse Biomedical K.K.



Manufacturing of 3D tissues and organs using a 3D bio-printer

The Group purchased a stake in September 2018.




Megakaryon Corp.



Development of platelet generation using iPS cells as raw material

The Group purchased a stake in February 2020.



Gene therapy

Gene Therapy Research Institution



Development of gene therapies using adeno-associated viruses

From May 2021

The Group and the Institution conduct joint development of revolutionary gene-therapy products.

The Group purchased a stake in March 2022.

Academic-Industrial Collaboration

- Joint R&D with the Facility for iPS Cell Therapy (FiT) at the CiRA Foundation

Pharmaceutical Sciences Field: 2nd Step: Cell-Culture Solutions

- We aim to expand our presence in the pharmaceutical sciences field, using medical plastics as an entry point. We will apply our expertise in plastic processing technology to address issues in the development and manufacture of new drug modalities.
- We are currently advancing in-house development of chemosynthetic scaffolding materials based on PVB plastics technology, a core Company technology.

Position of the Company's development themes and products for solving issues

The Company's development themes and products

1 Chemosynthetic scaffolding materials



2 Synthetic culture supplements



3 Cell-culture Medium



4 Cell-transport containers



5 Gene introduction




Sekisui Chemical core technologies

- PVA/B plastic design
- Fine-particle synthesis and design
- Injection molding processes

Application of plastics' safety, stability and ease of handling


Schematic view of cell-culture materials



Sekisui Chemical proposes cultivation materials that feature ✓ chemically defined, ✓ animal-free ✓ plastics-processing technology.

Cell-culture process and related issues

By contributing to stable production and low cost, these solutions contribute to industrialization of new modalities.



Issues

Issues in production processes

- Stabilization of culturing environment
- Contamination and infection risk in the manufacturing process

Issues in animal-derived materials

- Safety risks from animal-derived materials
- Quality variance

Application as original strengths for a new-modality CDMO

Synergy Field: Digital Health/Medical Devices

Digital Health

Housing business (daily living and Town and Community Development)

- Creating cities that bring health to those who live in them through treatment, diagnosis and prevention of illness

Residential

Advanced Lifeline



Treatment support, diagnosis and prevention

- Business creation in the new digital treatment field
- We aim to develop digital treatment programs in the disease area.

Life Science



Medical Devices

We expect to achieve synergies between a housing business that is closely connected to the way people live and diagnostics business and pharmaceutical sciences business that contribute to healthy and fulfilling living. Moreover, applying our strengths in plastics processing, we are examining scenarios for entering the medical-device business (treatment devices) and expanding our presence there.

Social issues with which the Sekisui Chemical Group is grappling

Achieving healthy and fulfilling living



Plastics (processing) + housing and nursing-care + medical care

Life Science

Residential

Innovative Mobility

Advanced Lifeline



New technologies

Examination of possibilities in M&A

Use of CVC



This slide presentation may contain forward-looking statements.

Such forward-looking statements are based on current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements due to changes in global economic, business, competitive market and regulatory factors.

Note: In the case of numerical values denominated in billions of yen, numbers below a billion are rounded up or down to the nearest hundred million